Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Bulletin Du Cancer
|
December 3, 2011
[How to evaluate renal function in cancer patients]
Vincent Launay-Vacher, Sarah Zimner-Rapuch, Olivier Moranne
Drugs
|
July 26, 2014
New therapies for hepatitis C: considerations in patients with renal impairment
Sarah Zimner-Rapuch, Nicolas Janus, Gilbert Deray, et al.
Clinical Drug Investigation
|
December 12, 2012
Pulmonary hypertension: use of oral drugs in patients with renal insufficiency
Sarah Zimner-Rapuch, Sabine Amet, Nicolas Janus, et al.
Drug Safety
|
February 2, 2013
Malaria prophylaxis in patients with renal impairment: a review
Sabine Amet, Sarah Zimner-Rapuch, Vincent Launay-Vacher, et al.
La Revue Du Praticien
|
April 21, 2012
[How to adjust the dose of drugs in chronic kidney disease?]
Vincent Launay-Vacher, Nicolas Janus, Sarah Zimner-Rapuch, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
April 17, 2021
Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
Sarah Zimner Rapuch, Victoria Divino, Kirsi Norrbacka, et al.
Journal of Medical Economics
|
April 23, 2026
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study
Lieven Annemans, Erin Johansson, Erik Spaepen, et al.
Diabetes, Obesity & Metabolism
|
April 29, 2026
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
Andreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, et al.
Cancer
|
April 17, 2014
Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients
Vincent Launay-Vacher, Sarah Zimner-Rapuch, Nicolas Poulalhon, et al.
Journal of Medical Economics
|
April 21, 2026
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
Erin Johansson, John P H Wilding, Navneet Upadhyay, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Bulletin Du Cancer
|
December 3, 2011
[How to evaluate renal function in cancer patients]
Vincent Launay-Vacher, Sarah Zimner-Rapuch, Olivier Moranne
Drugs
|
July 26, 2014
New therapies for hepatitis C: considerations in patients with renal impairment
Sarah Zimner-Rapuch, Nicolas Janus, Gilbert Deray, et al.
Clinical Drug Investigation
|
December 12, 2012
Pulmonary hypertension: use of oral drugs in patients with renal insufficiency
Sarah Zimner-Rapuch, Sabine Amet, Nicolas Janus, et al.
Drug Safety
|
February 2, 2013
Malaria prophylaxis in patients with renal impairment: a review
Sabine Amet, Sarah Zimner-Rapuch, Vincent Launay-Vacher, et al.
La Revue Du Praticien
|
April 21, 2012
[How to adjust the dose of drugs in chronic kidney disease?]
Vincent Launay-Vacher, Nicolas Janus, Sarah Zimner-Rapuch, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
April 17, 2021
Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
Sarah Zimner Rapuch, Victoria Divino, Kirsi Norrbacka, et al.
Journal of Medical Economics
|
April 23, 2026
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study
Lieven Annemans, Erin Johansson, Erik Spaepen, et al.
Diabetes, Obesity & Metabolism
|
April 29, 2026
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
Andreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, et al.
Cancer
|
April 17, 2014
Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients
Vincent Launay-Vacher, Sarah Zimner-Rapuch, Nicolas Poulalhon, et al.
Journal of Medical Economics
|
April 21, 2026
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
Erin Johansson, John P H Wilding, Navneet Upadhyay, et al.
Page
of 2